Untargeted sequencing of circulating microRNAs in a healthy and diseased older population

Lukas Streese, Philippe Demougin, Paula Iborra, Alexander Kanitz, Arne Deiseroth, Julia M Kröpfl, Arno Schmidt-Trucksäss, Mihaela Zavolan, Henner Hanssen, Lukas Streese, Philippe Demougin, Paula Iborra, Alexander Kanitz, Arne Deiseroth, Julia M Kröpfl, Arno Schmidt-Trucksäss, Mihaela Zavolan, Henner Hanssen

Abstract

We performed untargeted profiling of circulating microRNAs (miRNAs) in a well characterized cohort of older adults to verify associations of health and disease-related biomarkers with systemic miRNA expression. Differential expression analysis revealed 30 miRNAs that significantly differed between healthy active, healthy sedentary and sedentary cardiovascular risk patients. Increased expression of miRNAs miR-193b-5p, miR-122-5p, miR-885-3p, miR-193a-5p, miR-34a-5p, miR-505-3p, miR-194-5p, miR-27b-3p, miR-885-5p, miR-23b-5b, miR-365a-3p, miR-365b-3p, miR-22-5p was associated with a higher metabolic risk profile, unfavourable macro- and microvascular health, lower physical activity (PA) as well as cardiorespiratory fitness (CRF) levels. Increased expression of miR-342-3p, miR-1-3p, miR-92b-5p, miR-454-3p, miR-190a-5p and miR-375-3p was associated with a lower metabolic risk profile, favourable macro- and microvascular health as well as higher PA and CRF. Of note, the first two principal components explained as much as 20% and 11% of the data variance. miRNAs and their potential target genes appear to mediate disease- and health-related physiological and pathophysiological adaptations that need to be validated and supported by further downstream analysis in future studies.Clinical Trial Registration: ClinicalTrials.gov: NCT02796976 ( https://ichgcp.net/clinical-trials-registry/NCT02796976 ).

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Figure 1
Figure 1
Summary of analysis of EXAMIN AGE data. (A). Distribution of the number of individual miRNAs detected in specific numbers of samples and number and percentage of mature miRs identified in the indicated proportions of samples. (B). Numbers of miRNAs with specific values of median expression across samples (miRNAs with zero median expression are not shown). (C). Outline of the comparison of miRNA expression between groups of patients. DEA differential expression analysis, HA healthy active, HS healthy sedentary, SR sedentary at increased CV risk, FC fold change, FDR false discovery rate.
Figure 2
Figure 2
miRNA expression changes between conditions. (A) ‘Volcano plots’ showing the fold-change versus statistical significance measure for pairs of sample groups. (B) Mean versus fold-change expression of individual miRNAs in pairs of sample groups. HA healthy active, HS healthy sedentary, SR sedentary at increased CV risk, FDR false discovery rates, CPM count-per-million.
Figure 3
Figure 3
Relationship between miRNA expression levels and values of various physiological parameters. (A) Correlation coefficients have been calculated between the miRNA expression levels and the values of the indicated physiological parameters. (B) Fold-changes of the corresponding miRNAs among the indicated pairs of samples. (C) Median expression level of these miRNAs across samples (in counts per million, CPM). Fat fat mass, BMI body mass index, hipcirc hip circumference, hscrp high sensitive C-reactive protein, waistcirc waist circumference, sys_24h systolic blood pressure based on 24 h monitoring, dia_24h diastolic blood pressure based on 24 h monitoring, pwv pulse wave velocity, ldl low-density lipoprotein, tnf_alpha tumor necrosis factor alpha, CRVE central retinal venular equivalent, pwv_24h pulse wave velocity based on 24 h monitoring, CRAE central retinal arteriolar equivalent, ACC accelerometer, active activity counts, iop intraocular pressure, IL interleukin, AVR arteriolar-to-venular diameter ratio, hdl high-density lipoprotein, VO2peak peak oxygen uptake, HA healthy active individuals, HS healthy sedentary individuals, SR sedentary individuals with at least 2 cardiovascular risk factors.
Figure 4
Figure 4
Principal component analysis of the combined miRNA and physiological parameter data. (A) Projection of the data on the first two principal components, which explain ~ 20% and 11% of the variance. PC1 imperfectly separates the healthy active individuals from sedentary at risk. (B) PCA loadings of the first 30 variables contributing most to explaining the variance in the data (as indicated on the colour scale).

References

    1. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355.
    1. Feinberg MW, Moore KJ. MicroRNA regulation of atherosclerosis. Circ. Res. 2016;118:703–720.
    1. de Gonzalo-Calvo D, et al. Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: A novel tool for personalized medicine? Eur. Heart J. 2019;40:1643–1650.
    1. Navickas R, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: A systematic review. Cardiovasc. Res. 2016;111:322–337.
    1. Karakas M, et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study. Eur. Heart J. 2017;38:516–523.
    1. De Rosa S, et al. Transcoronary concentration gradients of circulating microRNAs. Circulation. 2011;124:1936–1944.
    1. De Rosa S, et al. Transcoronary concentration gradients of circulating microRNAs in heart failure. Eur. J. Heart Fail. 2018;20:1000–1010.
    1. Wang GK, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J. 2010;31:659–666.
    1. Hoefer IE, et al. Novel methodologies for biomarker discovery in atherosclerosis. Eur. Heart J. 2015;36:2635–2642.
    1. Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: Biomarkers or mediators of cardiovascular diseases? Arterioscler. Thromb. Vasc. Biol. 2011;31:2383–2390.
    1. Wang S, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell. 2008;15:261–271.
    1. Fish JE, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell. 2008;15:272–284.
    1. Schober A, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat. Med. 2014;20:368–376.
    1. Fichtlscherer S, et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 2010;107:677–684.
    1. Zampetaki A, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 2010;107:810–817.
    1. Bao F, Slusher AL, Whitehurst M, Huang CJ. Circulating microRNAs are upregulated following acute aerobic exercise in obese individuals. Physiol. Behav. 2018;197:15–21.
    1. Xu T, et al. Circulating microRNAs in response to exercise. Scand. J. Med. Sci. Sports. 2015;25:e149–e154.
    1. Zhou QL, et al. Circulating microRNAs in response to exercise training in healthy adults. Front. Genet. 2020 doi: 10.3389/fgene.2020.00256.
    1. Streese L, et al. Physical activity may drive healthy microvascular ageing via downregulation of p66(Shc) Eur. J. Prev. Cardiol. 2020;27:168–176.
    1. Zierath JR, Wallberg-Henriksson H. Looking ahead perspective: Where will the future of exercise biology take us? Cell Metab. 2015;22:25–30.
    1. Streese L, Deiseroth A, Schafer J, Schmidt-Trucksass A, Hanssen H. Exercise, arterial crosstalk-modulation, and inflammation in an aging population: The ExAMIN AGE study. Front. Physiol. 2018 doi: 10.3389/fphys.2018.00116.
    1. World-Medical-Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
    1. Berninger P, Gaidatzis D, van Nimwegen E, Zavolan M. Computational analysis of small RNA cloning data. Methods. 2008;44:13–21.
    1. Hoffmann S, et al. Fast Mapping of Short Sequences with Mismatches, Insertions and Deletions Using Index Structures. Plos Comput. Biol. 2009;5:e1000502.
    1. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
    1. Gumienny R, Zavolan M. Accurate transcriptome-wide prediction of microRNA targets and small interfering RNA off-targets with MIRZA-G. Nucleic Acids Res. 2015;43:9095.
    1. Hou Z, et al. Longterm exercise-derived exosomal miR-342-5p: A novel exerkine for cardioprotection. Circ. Res. 2019;124:1386–1400.
    1. Lu H, et al. Elevated circulating stearic acid leads to a major lipotoxic effect on mouse pancreatic beta cells in hyperlipidaemia via a miR-34a-5p-mediated PERK/p53-dependent pathway. Diabetologia. 2016;59:1247–1257.
    1. Liu CH, et al. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 2018;69:1335–1348.
    1. Willeit P, Skroblin P, Kiechl S, Fernandez-Hernando C, Mayr M. Liver microRNAs: Potential mediators and biomarkers for metabolic and cardiovascular disease? Eur. Heart J. 2016;37:3260–3266.
    1. Yu J, et al. MiR-27b-3p inhibition enhances browning of epididymal fat in high-fat diet induced obese mice. Front. Endocrinol. (Lausanne) 2019;10:38.
    1. Arias N, et al. MicroRNAs involved in the browning process of adipocytes. J. Physiol. Biochem. 2016;72:509–521.
    1. Gui JH, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin. Sci. 2011;120:183–193.
    1. Raitoharju E, et al. Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. Sci. Rep. 2016;6:38262.
    1. Liang TY, Lou JY. Increased expression of mir-34a-5p and clinical association in acute ischemic stroke patients and in a rat model. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2016;22:2950–2955.
    1. Chua CEL, Tang BL. miR-34a in neurophysiology and neuropathology. J. Mol. Neurosci. 2019;67:235–246.
    1. Wang Y, et al. Circulating miR-22-5p and miR-122-5p are promising novel biomarkers for diagnosis of acute myocardial infarction. J. Cell. Physiol. 2019;234:4778–4786.
    1. Zhang X, Gu H, Wang L, Huang F, Cai J. MiR-885-3p is down-regulated in peripheral blood mononuclear cells from T1D patients and regulates the inflammatory response via targeting TLR4/NF-kappaB signaling. J. Gene Med. 2020;22:e3145.
    1. Escate R, Mata P, Cepeda JM, Padreo T, Badimon L. miR-505-3p controls chemokine receptor up-regulation in macrophages: Role in familial hypercholesterolemia. FASEB J. 2018;32:601–612.
    1. Chen Z, et al. Inflammation-dependent downregulation of miR-194-5p contributes to human intervertebral disc degeneration by targeting CUL4A and CUL4B. J. Cell Physiol. 2019;234:19977–19989.
    1. Boureima Oumarou D, et al. Involvement of microRNA-23b-5p in the promotion of cardiac hypertrophy and dysfunction via the HMGB2 signaling pathway. Biomed. Pharmacother. 2019;116:108977.
    1. Qu Y, Zhang N. miR-365b-3p inhibits the cell proliferation and migration of human coronary artery smooth muscle cells by directly targeting ADAMTS1 in coronary atherosclerosis. Exp. Ther. Med. 2018;16:4239–4245.
    1. Khalyfa A, Kheirandish-Gozal L, Bhattacharjee R, Khalyfa AA, Gozal D. Circulating microRNAs as potential biomarkers of endothelial dysfunction in obese children. Chest. 2016;149:786–800.
    1. Li TR, et al. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin. Chim. Acta. 2011;412:66–70.
    1. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ. Res. 2007;101:59–68.
    1. Yang Q, et al. MicroRNA-505 identified from patients with essential hypertension impairs endothelial cell migration and tube formation. Int. J. Cardiol. 2014;177:925–934.
    1. Lee IM, et al. Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of disease and life expectancy. Lancet. 2012;380:219–229.
    1. Dufresne S, Rebillard A, Muti P, Friedenreich CM, Brenner DR. A review of physical activity and circulating miRNA expression: Implications in cancer risk and progression. Cancer Epidemiol. Biomark. Prev. 2018;27:11–24.
    1. Ray SL, et al. The role of miR-342 in vascular health. Study in subclinical cardiovascular disease in mononuclear cells, plasma, inflammatory cytokines and PANX2. Int. J. Mol. Sci. 2020;21:7217.
    1. Ai J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 2010;391:73–77.
    1. Kuwabara Y, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet. 2011;4:446–454.
    1. Wu T, et al. Serum exosomal MiR-92b-5p as a potential biomarker for acute heart failure caused by dilated cardiomyopathy. Cell Physiol. Biochem. 2018;46:1939–1950.
    1. Wu T, et al. Circulating exosomal miR-92b-5p is a promising diagnostic biomarker of heart failure with reduced ejection fraction patients hospitalized for acute heart failure. J. Thorac. Dis. 2018;10:6211.
    1. Poy MN, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–230.
    1. Sen S, et al. Myotrophin—Purification of a novel peptide from spontaneously hypertensive rat-heart that influences myocardial growth. J. Biol. Chem. 1990;265:16635–16643.
    1. Das B, et al. Nuclear co-translocation of myotrophin and p65 stimulates myocyte growth—Regulation by myotrophin hairpin loops. J. Biol. Chem. 2008;283:27947–27956.
    1. Das B, et al. Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure. Cardiovasc. Res. 2010;87:524–534.
    1. Huttlin EL, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545:505–509.
    1. Szklarczyk D, et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–D613.
    1. Zhang GH, et al. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. Br. J. Cancer. 2019;121:1069–1078.
    1. Liu L, et al. Endothelial forkhead box transcription factor P1 regulates pathological cardiac remodeling through transforming growth factor-beta 1-endothelin-1 signal pathway. Circulation. 2019;140:665–680.
    1. Dressel U, et al. A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. J. Biol. Chem. 2001;276:17007–17013.

Source: PubMed

3
Suscribir